A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (NCT06215118)
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
Who can join: Review the eligibility criteria below.
Location: Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
- University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach, Florida
- Sylvester Comprehensive Cancer Center- Doral — Doral, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Miami Hospital and Clinics — Miami, Florida
- Sylvester Comprehensive Cancer Center Kendall — Miami, Florida
- Sylvester Comprehensive Cancer Center Plantation — Plantation, Florida
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Winship Cancer Institute — Atlanta, Georgia
- Indiana CTSI Clinical Research Center (ICRC) — Indianapolis, Indiana
- Indiana University Health University Hospital — Indianapolis, Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC) — Indianapolis, Indiana
- University of Maryland — Baltimore, Maryland
- Brigham and Women's Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Dana-Farber Cancer Institute - Chestnut Hill — Newton, Massachusetts
- University of Massachusetts Chan Medical School — Worcester, Massachusetts
- Methodist Hospital — Omaha, Nebraska
- Oncology Hematology West P.C. dba Nebraska Cancer - Methodist — Omaha, Nebraska
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists — Omaha, Nebraska
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- MSK Basking Ridge — Basking Ridge, New Jersey
- MSK Monmouth — Middletown, New Jersey
- MSK Bergen — Montvale, New Jersey
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.